This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yasui, K. Articles by Inazawa, J. Search for Related Content PubMed PubMed Citation Articles by Yasui, K. Articles by Inazawa, J.

Alteration in Copy Numbers of Genes as a Mechanism for Acquired Drug Resistance

¹ Department of Molecular Cytogenetics, Medical Research Institute, Tokyo Medical and Dental University, Tokyo; ² Core Research for Evolutional Science and Technology of Japan Science and Technology Corporation, Kawaguchi; ³ Institute of Molecular and Cellular Biosciences, University of Tokyo, Tokyo; ⁴ Department of Clinical Medicine, Division of Molecular Diagnostics, Tohoku University, School of Medicine, Sendai; and ⁵ Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Chemoresistance is a major obstacle for successful treatment of cancer. To identify regions of the genome associated with acquired resistance to therapeutic drugs, we conducted molecular cytogenetic analyses of 23 cancer-cell lines, each resistant to either camptothecin, cisplatin, etoposide (VP-16), Adriamycin, or 1-ß-D-arabinofuranosylcytosine, although the parental tumor lines were not. Subtractive comparative genomic hybridization studies revealed regions of gain or loss in DNA-copy numbers that were characteristic of drug-resistant cell lines; i.e., differences from their drug-sensitive parental cell lines. Thirteen ATP-binding cassette (ABC) transporter genes [ABCA3, ABCB1 (MDR1), ABCB6, ABCB8, ABCB10, ABCB11, ABCC1 (MRP1), ABCC4, ABCC9, ABCD3, ABCD4, ABCE1, and ABCF2] were amplified among 19 of the resistant cell lines examined. Three genes encoding antiapoptotic BCL-2 proteins (BCL2L2, MCL1, and BCL2L10) were also amplified and consequently overexpressed in three of the derivative lines. Down-regulation of BCL2L2 with an antisense oligonucleotide sensitized a VP-16 resistant ovarian-cancer cell line (SKOV3/VP) to VP-16. A decrease in copy numbers of genes encoding deoxycytidine kinase, DNA topoisomerase I, and DNA topoisomerase II reduced their expression levels in one cytosine arabinoside-resistant line, two of three camptothecin-resistant lines, and two of five VP-16-resistant cell lines, respectively. Our results indicated that changes in DNA-copy numbers of the genes mentioned can activate or down-regulate them in drug-resistant cell lines, and that such genomic alterations might be implicated in acquired chemoresistance.

This article has been cited by other articles:

				M. C. Zatelli, A. Luchin, F. Tagliati, S. Leoni, D. Piccin, M. Bondanelli, R. Rossi, and E. C degli Uberti Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression Endocr. Relat. Cancer, December 1, 2007; 14(4): 1029 - 1038. [Abstract] [Full Text] [PDF]

				Y.-H. Lin, J. Friederichs, M. A. Black, J. Mages, R. Rosenberg, P. J. Guilford, V. Phillips, M. Thompson-Fawcett, N. Kasabov, T. Toro, et al. Multiple Gene Expression Classifiers from Different Array Platforms Predict Poor Prognosis of Colorectal Cancer Clin. Cancer Res., January 15, 2007; 13(2): 498 - 507. [Abstract] [Full Text] [PDF]

				N. Auger, J. Thillet, K. Wanherdrick, A. Idbaih, M.-E. Legrier, B. Dutrillaux, M. Sanson, and M.-F. Poupon Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line. Mol. Cancer Ther., September 1, 2006; 5(9): 2182 - 2192. [Abstract] [Full Text] [PDF]

				T. Efferth, J.-P. Gillet, A. Sauerbrey, F. Zintl, V. Bertholet, F. de Longueville, J. Remacle, and D. Steinbach Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia. Mol. Cancer Ther., August 1, 2006; 5(8): 1986 - 1994. [Abstract] [Full Text] [PDF]

				D. Steinbach, J.-P. Gillet, A. Sauerbrey, B. Gruhn, K. Dawczynski, V. Bertholet, F. de Longueville, F. Zintl, J. Remacle, and T. Efferth ABCA3 as a Possible Cause of Drug Resistance in Childhood Acute Myeloid Leukemia. Clin. Cancer Res., July 15, 2006; 12(14): 4357 - 4363. [Abstract] [Full Text] [PDF]

				D.-W. Shen, X.-J. Liang, T. Suzuki, and M. M. Gottesman Identification by Functional Cloning from a Retroviral cDNA Library of cDNAs for Ribosomal Protein L36 and the 10-kDa Heat Shock Protein that Confer Cisplatin Resistance Mol. Pharmacol., April 1, 2006; 69(4): 1383 - 1388. [Abstract] [Full Text] [PDF]

				M. A. van de Wiel, J. L. Costa, K. Smid, C. B.M. Oudejans, A. M. Bergman, G. A. Meijer, G. J. Peters, and B. Ylstra Expression Microarray Analysis and Oligo Array Comparative Genomic Hybridization of Acquired Gemcitabine Resistance in Mouse Colon Reveals Selection for Chromosomal Aberrations Cancer Res., November 15, 2005; 65(22): 10208 - 10213. [Abstract] [Full Text] [PDF]

				M. C. Zatelli, A. Luchin, D. Piccin, F. Tagliati, A. Bottoni, C. Vignali, M. Bondanelli, and E. C. degli Uberti Cyclooxygenase-2 Inhibitors Reverse Chemoresistance Phenotype in Medullary Thyroid Carcinoma by a Permeability Glycoprotein-Mediated Mechanism J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5754 - 5760. [Abstract] [Full Text] [PDF]

				H. Tsuda, Y. M. Ito, Y. Ohashi, K.-K. Wong, Y. Hashiguchi, W. R. Welch, R. S. Berkowitz, M. J. Birrer, and S. C. Mok Identification of Overexpression and Amplification of ABCF2 in Clear Cell Ovarian Adenocarcinomas by cDNA Microarray Analyses Clin. Cancer Res., October 1, 2005; 11(19): 6880 - 6888. [Abstract] [Full Text] [PDF]

				J. A.E. Irving, L. Bloodworth, N. P. Bown, M. C. Case, L. A. Hogarth, and A. G. Hall Loss of Heterozygosity in Childhood Acute Lymphoblastic Leukemia Detected by Genome-Wide Microarray Single Nucleotide Polymorphism Analysis Cancer Res., April 15, 2005; 65(8): 3053 - 3058. [Abstract] [Full Text] [PDF]